Skip to main content
Egyptian Journal of Medical Human Genetics

Table 3 Correlation between methylation status of TSGs and the clinicopathological parameters in 50 HCC tissues

From: Significance of promoter methylation of multiple tumor suppressor genes in hepatocellular carcinoma

  

RASSF1A

X2

CHFR

X2

MGMT

X2

GSTP1

X2

hMLH1

X2

 

(N)

M

U

P

M

U

P

M

U

P

M

U

P

M

U

P

Sex

F(11)

8 (73%)

3 (27%)

0.38

9 (82%)

2 (18%)

0.2

6 (54.5%)

5 (45.5%)

0.58

3 (27%)

8 (73%)

0.14

1 (10%)

10 (90%)

0.51

 

M (39)

32 (82%)

7 (18%)

 

26 (67%)

13 (33%)

 

22 (56%)

17 (44%)

 

20 (51%)

19 (49%)

 

6 (15%)

33 (85%)

 

Age

 < 55 (16)

14 (87.5%)

2 (12.5%)

0.30

11 (69%)

5 (31%)

0.57

9 (56%)

7 (44%)

0.61

11 (69%)

5 (31%)

0.02*

2 (12.5%)

14 (87.5%)

0.60

 

 > 55 ( 34)

26 (76.5%)

8 (23.5%)

 

24 (71%)

10 (29%)

 

19 (56%)

15 (44%)

 

12 (35%)

22 65%)

 

5 (15%)

30 (85%)

 

Grade

GII (37)

30 (81%)

7 (19%)

0.51

25 (68%)

12 (32%)

0.39

18 (49%)

19 (51%)

0.07

18 (49%)

19 (51%)

0.38

3 (8%)

34 (92%)

0.06

 

GIII (13)

10 (77%)

3 (23%)

 

10 (77%)

3 (23%)

 

10 (77%)

3 (23%)

 

5 (38.5%)

8 (61.5%)

 

4 (31%)

9 (69%)

 

Size

 < 3 cm (10)

9 (90%)

1 (10%)

0.34

7 (70%)

3 (30%)

0.63

5 (50%)

5 (50%)

0.46

5 (50%)

5 (50%)

0.52

1 (10%)

9 (90%)

0.57

 

 > 3 m (40)

31 (77.5%)

9 (22.5%)

 

28 (70%)

12 (30%)

 

23 (57.5%)

17 (42.5%)

 

18 (45%)

22 (55%)

 

6 (15%)

34 (85%)

 

FL

Mul. (15)

14 (93%)

1 (7%)

0.12

12 (80%)

3 (20%)

0.25

7 (47%)

8 (53%)

0.28

10 (67%)

5 (33%)

0.05

2 (13%)

13 (87%)

0.65

 

Sol. (35)

26 (74%)

9 (26%)

 

23 (66%)

12 (34%)

 

21 (60%)

14 (40%)

 

13 (37%)

22 (63%)

 

5 (14%)

30 (86%)

 

LC

Yes(38)

31 (82%)

7 (18%)

0.44

27 (71%)

11 (29%)

0.51

22 (58%)

16 (42%)

0.43

18 (47%)

20 (53%)

0.49

5 (13%)

33 (87%)

0.54

 

No(12)

9 (75%)

3 (25%)

 

8 (67%)

4 (33%)

 

6 (50%)

6 (50%)

 

5 (42%)

7 (58%)

 

2 (17%)

10 (83%)

 

OYS

No (32)

30 (94%)

2 (6%)

0.01*

28 (87.5%)

4 (12.5%)

0.01*

23 (72%)

9 (28%)

0.01*

15 (47%)

17 (53%)

0.5

7 (22%)

25 (78%)

0.03

 

Yes (18)

10 (56%)

8 (44%)

 

7 (39%)

11 (61%)

 

5 (28%)

13 (72%)

 

8 (44%)

10 (56%)

 

0 (0%)

18 (100.%)

 

FYR

No (10)

1 (10%)

9 (90%)

0.01*

3 (30%)

7 (70%)

0.04*

2 (20%)

8 (80%)

0.01*

1 (10%)

9 (90%)

0.01*

0 (0.0%)

10 (100.%)

0.18

 

Yes (40)

39 (97.5%)

1 (2.5%)

 

32 (80%)

8 (20%)

 

26 (65%)

14 (35%)

 

22 (55%)

18 (45%)

 

7 (17.5%)

33 (82.5%)

 

AFP

 < 20 ng/l (25)

19 (76%)

6 (24%)

0.36

16 (64%

9 (36%)

0.26

12 (48%)

13 (52%)

0.19

11 (44%)

14 (56%)

0.50

2 (8%)

23 (92%)

0.20

 

 > 30 ng/ml (25)

21 (84%)

4 (16%)

 

19 (76%

6 (24%)

 

16 (64%)

9 (36%)

 

12 (48%)

13 (52%)

 

5 (20%)

20 (80%)

 
  1. HCC: hepatocellular carcinoma, ANT: adjacent non-tumorous tissue, U: unmethylation, P: partially methylation, M: methylation. Mul: multiple, Sol: solitary, FL: focal lesion, LC: liver cirrhosis, OYS: one- year survival, FYR: first-year recurrence, AFP: alpha-feto protein, *P value < 0.05 indicates statistical significance determined using the Pearson's χ2 test and Fisher’s exact test
Back to article page